Seattle-based Omeros said today that it has launched an initial public offering of 6.82 million shares of its common stock. According to the firm, it estimates that pricing for the IPO will be between $10.00 and $12.00 per share. Omeros is looking to list on the NASDAQ Global Market as "OMER". The IPO is being underwritten by Deutsche Bank Securities, Wedbush PacGrow Life Sciences, Canaccord Adams, Needham & Company, and Chicago Investment Group and national Securities Corporation. The firm said that proceeds of the offering would go to fund completion of Phase 3 clinical trials for its lead product candidate, OMS103HP, which is being evaluated for use to improve postoperative joint function ater arthroscopic surgery.